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Abstract Pulmonary arterial hypertension (PAH) is a chronic
and progressive disease which continues to carry an unaccept-
ably highmortality and morbidity. The nitric oxide (NO) path-
way has been implicated in the pathophysiology and progres-
sion of the disease. Its extremely short half-life and systemic
effects have hampered the clinical use of NO in PAH. In an
attempt to circumvent these major limitations, we have devel-
oped a new NO-nanomedicine formulation. The formulation
was based on hydrogel-like polymeric composite NO-releas-
ing nanoparticles (NO-RP). The kinetics of NO release from
the NO-RP showed a peak at about 120 min followed by a
sustained release for over 8 h. The NO-RP did not affect the
viability or inflammation responses of endothelial cells. The
NO-RP produced concentration-dependent relaxations of pul-
monary arteries in mice with PAH induced by hypoxia. In
conclusion, NO-RP drugs could considerably enhance the
therapeutic potential of NO therapy for PAH.
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Pulmonary arterial hypertension (PAH) continues to carry
very poor prognosis in terms of both survival and quality of
life in spite of the use of modern combination therapy [1]. This
could be, at least in part, due to the fact that the exact molec-
ular mechanisms remain largely unknown. The pathophysiol-
ogy of the disease includes pulmonary vasospasm, vascular
remodeling, and right ventricular failure. Several pathways
have been implicated in the pathophysiology of PAH [2].
This has stimulated development of agents that can influence
these pathways. One of the most promising strategies is mod-
ulating the nitric oxide (NO) pathway due to the apparent
central role of NO in this disease [3]. NO is a potent vasodi-
lator with anti-proliferative and anti-coagulant effects [3].
Several attempts at using inhaled NO gas in humans with both
acute and chronic PAH have been tried [4]. The effect of NO
gas is grossly limited by its short half-life and metabolism of
cGMP by phosphodiesterase (type I and V) enzymes. In
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addition, adverse effects limit the systemic use of NO donors.
Some of these limitations could be overcome by inha-
lation therapy particularly if combined with the use of a
slow release nanoparticle formulation. There are several
types of particles that may be useful as carriers of NO
for the treatment of PAH including polymeric carriers
[5]. Polymers have the advantage as potential drug car-
riers because they are biocompatible and their surface can
be readily modified [5].
In an attempt to circumvent these major limitations,
we have developed and performed extensive preclinical
testing of a new NO-nanomedicine formulation. The NO-
releasing polymers (NO-RPs) were prepared via
ionotropic gelation technique. In brief, acidic solution
of methyl silicate (2.8 ml/ml) was sonicated in ice bath
at a power of 45 kW with 10 s pulse on and 5 s pulse
off, followed by adding 1.1 ml of oligochitosan solution
(0.5 % w/v, 15 KDa), polyvinylpyrrolidone (6.25 mg,
40 kDa), and 2.1 ml of polyethylene glycol (0.4 kDa)
with stirring for 5 min. Afterwards, 15 ml of nitrite so-
lution (3 % w/v) containing a predetermined weight of
reducing agent was added followed by dropwise addition
of 5 ml aqueous sodium tripolyphosphate (0.08 % w/v)
with stirring. The resulting mixture was left at ambient
temperature for 30 min followed by freeze-drying. The
NO-RPs were characterized using Fourier transform in-
frared, X-ray diffraction, differential scanning calorime-
try, scanning electron microscopy (SEM) and high-
resolution transmission electron microscopy (HR-TEM).
The particle size, as determined by dynamic light scat-
tering, was in the range of 200–230 nm. This size was
also confirmed using SEM and HR-TEM, which dem-
onstrated a fine structure of the NO-RPs particles with a
non-spherical morphology (Fig. 1a).
In aqueous solution, simulating in vivo conditions,
the NO-RP released NO in a concentration dependent
manner with steady-state kinetics noted at 6.6 min
(Fig. 1b) compared to NO release by SNP which was
6-times higher than the NO-RP at the same time point.
When measured up to 8 h, NO release from the NO-
RPs at a concentration of 5 mg/ml revealed two phases
with an early peak lasting approximately 120 min
followed by a decline (approximately 50 %) and a
new steady state lasting for at least 8 h (Fig. 1c).
When hemoglobin was added to the reaction mixture
containing either NPs or SNP, NO release (measured
by an NO-electrode) was quenched, confirming that free
NO, rather than a higher oxide, was being detected.
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Fig. 1 a (i) A schematic illustration of the development of the NO-
releasing polymer and transmission electron microscopy image of the
particles, size and morphology of the NO-releasing polymers as
determined by (ii) dynamic light scattering and (iii) scanning electron
microscopy at ×3035. b NO release from different concentrations of
NO-releasing polymers (NO-RPs). Measurements were recorded using
NO measuring electrode over a period of 20 min. c NO release
pharmacokinetics from the NO-releasing polymers (NO-RPs).
Measurements were recorded using NO measuring electrode over a
period of 8 h. d Effect of NO-releasing polymer (NO-RP) on pre-
contracted pulmonary artery from control mice and mice with
pulmonary arterial hypertension. Data represents mean ± SEM for n = 3
from three animals. Statistical significance was determined by two-way
ANOVA followed by a Bonferroni post hoc test (*p< 0.05)
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At concentrations up 10mg/ml both control and the NO-
RPs showed no effect on viability of endothelial cells under
control culture conditions or in experiments where LPS was
added to induce inflammation. Similarly, NO-RPs had no ef-
fect on basal or LPS-induced CXCL8 release from endothelial
cells. The NO-RPs demonstrated no effect on pulmonary ar-
tery smooth muscle cell viability.
NO-RPs induced concentration-dependent relaxations of
both aorta and pulmonary arteries (Fig. 1d). It was interesting
to note that the NO-RPs appeared selective for vessels from
mice with pulmonary hypertension displaying an increased
EC50 compared to pulmonary arteries from control mice.
SNP similarly induced vasodilator responses in pulmonary
artery from both control mice and mice with pulmonary
hypertension.
The current findings are essentially preliminary in nature
and these findings need to be investigated further with addi-
tional experiments. In vivo studies with NO-RPs are required
as there is a need to establish a clear benefit over existing
therapeutic strategies in use of these molecules in the treat-
ment of PAH.
These observations do show that NO-RPs (i) release
free NO in aqueous solution, (ii) are non-toxic to cells
and (iii) relax systemic (aorta) and pulmonary vessels.
Our findings that this novel class of molecules appeared
to selectively target vessels from mice with pulmonary
hypertension is interesting and supports the idea that
these preparations may be useful in the treatment of
human disease.
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